economic models

Summary

Summary: Statistical models of the production, distribution, and consumption of goods and services, as well as of financial considerations. For the application of statistics to the testing and quantifying of economic theories MODELS, ECONOMETRIC is available.

Top Publications

  1. ncbi Validation of health economic models: the example of EVITA
    Thomas Hammerschmidt
    GlaxoSmithKline, Munich, Germany
    Value Health 6:551-9. 2003
  2. pmc The role of social cognition in decision making
    Chris D Frith
    Center for Functional Integrative Neuroscience, Aarhus University Hospital, Nørrebrogade 44, Building 30, 8000 Arhus C, Denmark
    Philos Trans R Soc Lond B Biol Sci 363:3875-86. 2008
  3. ncbi Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data
    Steven Crowley
    GlaxoSmithKline Research and Development, London, United Kingdom
    J Gastroenterol Hepatol 17:153-64. 2002
  4. ncbi Willingness to pay for health insurance in a developing economy. A pilot study of the informal sector of Ghana using contingent valuation
    W K Asenso-Okyere
    University of Ghana, Legon
    Health Policy 42:223-37. 1997
  5. ncbi Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
    Michael Spencer
    Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
    Pharmacoeconomics 23:619-37. 2005
  6. ncbi Economic models in type 2 diabetes
    Y Yi
    Mapi Values, Bollington, Macclesfield, UK
    Curr Med Res Opin 26:2105-18. 2010
  7. pmc Neural correlates of economic game playing
    Frank Krueger
    Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1440, USA
    Philos Trans R Soc Lond B Biol Sci 363:3859-74. 2008
  8. ncbi Are adverse effects incorporated in economic models? An initial review of current practice
    D Craig
    CRD CHE Technology Assessment Group Centre for Reviews and Dissemination Centre for Health Economics, University of York, UK
    Health Technol Assess 13:1-71, 97-181, iii. 2009
  9. pmc Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
    Beate Sander
    Department of Health Policy, Management and Evaluation, University of Toronto, Canada
    Value Health 12:226-33. 2009
  10. ncbi A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    S King
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 10:iii-iv, xiii-146. 2006

Detail Information

Publications233 found, 100 shown here

  1. ncbi Validation of health economic models: the example of EVITA
    Thomas Hammerschmidt
    GlaxoSmithKline, Munich, Germany
    Value Health 6:551-9. 2003
    ..The objective of this study was to illustrate the efforts undertaken to validate the EVITA model...
  2. pmc The role of social cognition in decision making
    Chris D Frith
    Center for Functional Integrative Neuroscience, Aarhus University Hospital, Nørrebrogade 44, Building 30, 8000 Arhus C, Denmark
    Philos Trans R Soc Lond B Biol Sci 363:3875-86. 2008
    ..In these cases, social motivations and emotions compete with each other, while higher-level control processes modulate the interactions of these low-level biases...
  3. ncbi Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data
    Steven Crowley
    GlaxoSmithKline Research and Development, London, United Kingdom
    J Gastroenterol Hepatol 17:153-64. 2002
    ..This study estimates clinical outcomes and cost-effectiveness of lamivudine compared with other treatment scenarios for CHB, from an Australian health-care provider perspective...
  4. ncbi Willingness to pay for health insurance in a developing economy. A pilot study of the informal sector of Ghana using contingent valuation
    W K Asenso-Okyere
    University of Ghana, Legon
    Health Policy 42:223-37. 1997
    ..As income increases, or the proportion of unemployed household members drop, people are willing to pay higher premiums for health insurance...
  5. ncbi Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
    Michael Spencer
    Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
    Pharmacoeconomics 23:619-37. 2005
    ....
  6. ncbi Economic models in type 2 diabetes
    Y Yi
    Mapi Values, Bollington, Macclesfield, UK
    Curr Med Res Opin 26:2105-18. 2010
    ..To identify and critically appraise cost-effectiveness models developed to evaluate type 2 diabetes (T2D) treatments and to assess which types of treatment effects they capture...
  7. pmc Neural correlates of economic game playing
    Frank Krueger
    Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1440, USA
    Philos Trans R Soc Lond B Biol Sci 363:3859-74. 2008
    ....
  8. ncbi Are adverse effects incorporated in economic models? An initial review of current practice
    D Craig
    CRD CHE Technology Assessment Group Centre for Reviews and Dissemination Centre for Health Economics, University of York, UK
    Health Technol Assess 13:1-71, 97-181, iii. 2009
    To identify methodological research on the incorporation of adverse effects in economic models and to review current practice.
  9. pmc Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
    Beate Sander
    Department of Health Policy, Management and Evaluation, University of Toronto, Canada
    Value Health 12:226-33. 2009
    ..To project the potential economic impact of pandemic influenza mitigation strategies from a societal perspective in the United States...
  10. ncbi A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    S King
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 10:iii-iv, xiii-146. 2006
    ....
  11. ncbi Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute for Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vaccine 23:5365-71. 2005
    ..To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands...
  12. ncbi On future non-medical costs in economic evaluations
    Bengt Liljas
    AstraZeneca, Molndal, Sweden
    Health Econ 17:579-91. 2008
    ..Until we have answers to these areas for future research, it seems premature to include future non-medical costs...
  13. ncbi Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza
    K L Nichol
    Medicine Service 111, Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
    Arch Intern Med 161:749-59. 2001
    ..This group is not included among the traditional priority groups for annual vaccination. Immunization rates remain low...
  14. ncbi Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
    Adam Lloyd
    Fourth Hurdle Consulting Ltd, London, WC1V 6PL, UK
    Eur J Health Econ 9:7-15. 2008
    ....
  15. ncbi Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis
    Fangjun Zhou
    National Immunization Program, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia 30333, USA
    Pediatrics 110:653-61. 2002
    ..To evaluate the economic impact of universal Haemophilus influenzae type b (Hib) vaccination starting at 2 months of age...
  16. ncbi Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
    M F Drummond
    Centre for Health Economics, University of York, Heslington, York, YO10 5DD, United Kingdom
    Med Decis Making 25:520-33. 2005
    ..To compare the analytic judgments, data, and assumptions of different models used in the economic evaluation of infliximab, one of a new class of drugs for rheumatoid arthritis (RA)...
  17. pmc Assessing the costs and benefits of an oral vaccine for raccoon rabies: a possible model
    M I Meltzer
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Emerg Infect Dis 2:343-9. 1996
    ....
  18. pmc Cost-benefit of stockpiling drugs for influenza pandemic
    Ran D Balicer
    Ministry of Health, Jerusalem, Israel
    Emerg Infect Dis 11:1280-2. 2005
    ..Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts...
  19. ncbi The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm
    Helen Campbell
    Health Economics Research Centre, Department of Public Health, University of Oxford, UK
    J Health Serv Res Policy 12:11-7. 2007
    To review health economic models of population screening for abdominal aortic aneurysm (AAA) among elderly males and assess their credibility for informing decision-making.
  20. ncbi Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
    Joshua A Ray
    CORE Center for Outcomes Research, A Unit of IMS, Allschwil Basel, Switzerland
    Curr Med Res Opin 23:609-22. 2007
    ....
  21. ncbi Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness
    Michael Schlander
    Institute for Innovation and Valuation in Health Care, Eschborn, Germany
    Eur Child Adolesc Psychiatry 16:421-9. 2007
    ..Limitations of currently available economic evaluations include their short time horizon, and future research should assess treatment effects on long-term sequelae associated with ADHD...
  22. ncbi Economic models of antiretroviral therapy: searching for the optimal strategy
    Fred J Hellinger
    Center for Delivery, Organization and Markets, Agency for Healthcare Research and Quality AHRQ, Rockville, Maryland 20850, USA
    Pharmacoeconomics 24:631-42. 2006
    ..Moreover, it was found that estimates of drug costs in these models may not accurately reflect actual expenditures...
  23. ncbi Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination
    M Jit
    Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London, United Kingdom
    Vaccine 25:3971-9. 2007
    ..Two rotavirus vaccines (RotaTeq and Rotarix) have recently completed clinical trials. We investigated whether routine infant immunisation with either vaccine can be cost effective...
  24. ncbi Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries
    Richard D Rheingans
    Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, USA
    Rev Panam Salud Publica 21:205-16. 2007
    ..To estimate the costs, benefits and cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil, Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela...
  25. ncbi Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales
    A Melegaro
    Modelling and Economics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 22:4203-14. 2004
    ..To establish whether universal vaccination of infants with the pneumococcal conjugate vaccine is likely to be cost-effective from the perspective of the health care provider (NHS)...
  26. ncbi A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom
    Suzi Cottrell
    IMS Health, London, UK
    Value Health 11:376-88. 2008
    ..To estimate the cost-effectiveness of atomoxetine for children with attention-deficity/hyperactivity disorder (ADHD) in the United Kingdom compared with current alternatives...
  27. ncbi An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada
    R A Zabinski
    Pharmacia Corporation, Global Health Outcomes, Skokie, Illinois, USA
    Pharmacoeconomics 19:49-58. 2001
    ....
  28. ncbi Neuroeconomics: the consilience of brain and decision
    Paul W Glimcher
    Center for Neural Science, New York University, New York, NY 10003, USA
    Science 306:447-52. 2004
    ..This review describes recent developments in neuroeconomics from both behavioral and biological perspectives...
  29. ncbi Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands
    G A A Hubben
    Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, University of Groningen, and Base Case, Healthcare Decision Support, Groningen, The Netherlands
    Vaccine 25:3669-78. 2007
    ....
  30. ncbi Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage
    Stephanie R Earnshaw
    RTI Health Solutions, Research Triangle Park, NC, USA
    Stroke 37:2751-8. 2006
    ..In the current analysis, we examine the cost-effectiveness of early treatment with rFVIIa for ICH in the United States...
  31. ncbi A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy
    Aslam H Anis
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    Pharmacoeconomics 24:387-400. 2006
    ..Incorporating the results found in the LIFE study into an economic model, an incremental cost-effectiveness analysis was performed comparing losartan with atenolol in the treatment of 67-year old patients with hypertension and LVH...
  32. ncbi Comparing the costs of three sealant delivery strategies
    S O Griffin
    Centers for Disease Control and Prevention Division of Oral Health Surveillance, Investigations and Research Branch, 4770 Buford Highway, MSF10, Chamblee, GA 30341, USA
    J Dent Res 81:641-5. 2002
    ..If sealant costs decreased to $6.00 (reported cost for school programs), TARGET dominated SN for caries increments exceeding 0.007 surfaces, and SA dominated TARGET for caries increments exceeding 0.034 surfaces...
  33. pmc Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico
    Atanacio Valencia-Mendoza
    Division of Health Economics, National Institute of Public Health, Av Universidad No 655, Col Santa Maria Ahuacatitlan, Cuernavaca, Morelos, 62508, Mexico
    BMC Infect Dis 8:103. 2008
    ..The objective of this study was to assess the cost-effectiveness of including the pentavalent rotavirus vaccine in Mexico's national immunisation program...
  34. ncbi Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
    E Marseille
    Health Strategies International, Orinda, CA 94563, USA
    Lancet 354:803-9. 1999
    ..Identification of economical interventions to decrease HIV-1 transmission to children is an urgent public-health priority in sub-Saharan Africa. We assessed the cost effectiveness of the HIVNET 012 nevirapine regimen...
  35. pmc Effect of cigarette tax increase on cigarette consumption in Taiwan
    J M Lee
    Department of Logistic Management, National Kaohsiung Marine University, Kaohsiung, Taiwan
    Tob Control 14:i71-5. 2005
    ..This study evaluates the effect of a 5 New Taiwan Dollar (NTD 5) Health and Welfare Tax increase on the consumption of domestic and imported cigarettes and cigars...
  36. ncbi Eliciting expert opinion for economic models: an applied example
    Jose Leal
    Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Oxford, UK
    Value Health 10:195-203. 2007
    ..Our objective was to develop a practical computer-based tool for eliciting expert opinion about the shape of the uncertainty distribution around individual model parameters...
  37. ncbi [Cost of mother-child care in Morelos State]
    Lucero Cahuana-Hurtado
    Instituto Nacional de Salud Publica, Centro de Investigación en Sistemas de Salud, Dirección de Economía y Políticas de la Salud, Cuernavaca, Morelos, Mexico
    Salud Publica Mex 46:316-25. 2004
    ..To compare the cost of maternal and child health care (current model) to that of the WHO Mother-Baby Package if it were implemented...
  38. pmc Increasing taxes to reduce smoking prevalence and smoking attributable mortality in Taiwan: results from a tobacco policy simulation model
    D T Levy
    Pacific Institute for Research and Evaluation, University of Baltimore, Baltimore, Maryland, USA
    Tob Control 14:i45-50. 2005
    ..To develop a simulation model to predict the effects of tax policies on smoking prevalence rates and smoking attributable deaths...
  39. pmc Intangibility in intertemporal choice
    Scott Rick
    Department of Operations and Information Management, Wharton School, University of Pennsylvania, Philadelphia, PA 19104, USA
    Philos Trans R Soc Lond B Biol Sci 363:3813-24. 2008
    ..Although most progress has been made in the domain of spending and saving, we discuss how the existing neuroeconomic research could be extended to other domains where trade-offs are ill defined...
  40. pmc Methods of data collection and analysis for the economic evaluation alongside a national, multi-centre trial in the UK: conventional ventilation or ECMO for Severe Adult Respiratory Failure (CESAR)
    Mariamma M Thalanany
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, UK
    BMC Health Serv Res 8:94. 2008
    ..Given the high cost of treatment, ECMO is considered an expensive technology for many funding systems. However, conventional treatment for severe respiratory failure is also one of the more costly forms of care in any health system...
  41. ncbi Practical guidelines for economic evaluations alongside equivalence trials
    Judith E Bosmans
    Health Technology Assessment Unit, Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Value Health 11:251-8. 2008
    ..The concepts described in the article are illustrated using the results from an economic noninferiority trial...
  42. ncbi Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts
    Mohan V Bala
    Centocor Inc, Malvern, Pennsylvania 19355, USA
    Pharmacoeconomics 24:345-54. 2006
    ..Even with its limitations, Markov decision models offer an opportunity for health economists to inform healthcare decision-makers on how to modify current treatment pathways to incorporate new treatments as they become available...
  43. ncbi A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder
    Edward P Armstrong
    College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
    Curr Med Res Opin 24:1115-21. 2008
    ..To estimate the costs and quality-adjusted life weeks of duloxetine and escitalopram...
  44. ncbi Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System
    Wei Shi Yeh
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA
    Pharmacotherapy 27:813-24. 2007
    ....
  45. ncbi Economic cost of age-related macular degeneration: a review of recent research
    Kathleen M Ke
    School of Economics and Politics, University of Ulster, Newtownabbey, UK
    Drugs Aging 23:217-25. 2006
    ..We further argue that significant gaps in our understanding of the costs of AMD (particularly in respect of indirect costs) also exist. Current research should be augmented by more comprehensive studies...
  46. ncbi Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
    ..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
  47. pmc Economic gains and health benefits from a new cigarette tax scheme in Taiwan: a simulation using the CGE model
    Chun Yuan Ye
    Department of International Trade, Overseas Chinese Institute of Technology, Taichung, Taiwan
    BMC Public Health 6:62. 2006
    ..This study evaluates the impact of an increase in cigarette tax in Taiwan in terms of the effects it has on the overall economy and the health benefits that it brings...
  48. pmc Cost effectiveness of chest pain unit care in the NHS
    Yemi Oluboyede
    Health Economics and Decision Science HEDS, School of Health and Related Research, University of Sheffield, 30 Regent Street, Sheffield, UK
    BMC Health Serv Res 8:174. 2008
    ....
  49. ncbi Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005
    ..8 million. Investment in a proton facility may thus be cost-effective. The results must be interpreted with caution, since there is a lack of data, and consequently large uncertainties in the assumptions used...
  50. ncbi A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children
    Pia M Johansson
    Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden
    Scand J Public Health 33:343-52. 2005
    ..The second aim was to apply the model estimates to a smoking cessation intervention...
  51. ncbi The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace
    J A Sollano
    GlaxoSmithKline, King of Prussia, Pennsylvania, USA
    Clin Pharmacol Ther 84:263-6. 2008
    ..We propose a new model of valuation of pharmacotherapies that attempts to secure an adequate return on investment in innovation by ensuring optimal pricing and reimbursement...
  52. ncbi Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy
    John T Schousboe
    Park Nicollet Health Services, Minneapolis, MN, USA
    Osteoporos Int 16:1883-93. 2005
    ....
  53. ncbi Using pharmacoeconomics to value pharmacotherapy
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
    Clin Pharmacol Ther 84:197-200. 2008
    ....
  54. ncbi Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness
    Kamal Desai
    Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, UK
    AIDS 22:1829-39. 2008
    ..We assess the expected number of HIV cases prevented and cost-effectiveness of a hypothetical HIV chemoprophylaxis program among men who have sex with men in a large US city...
  55. pmc Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study
    Steven M Kymes
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Ophthalmol 141:997-1008. 2006
    ..There is no consensus on which people with ocular hypertension would benefit from treatment...
  56. pmc Cost-effective osteoporosis treatment thresholds: the United States perspective
    A N A Tosteson
    Multidisciplinary Clinical Research Center in Musculoskeletal Diseases and The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, Lebanon, NH 03756, USA
    Osteoporos Int 19:437-47. 2008
    ..A 3% 10-year risk of hip fracture was generally required for osteoporosis treatment to cost less than $60,000 per QALY gained...
  57. ncbi Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling
    Christophe Pinget
    Health Technology Assessment Unit, Lausanne University Hospital, Switzerland
    Eur J Cardiovasc Prev Rehabil 14:451-5. 2007
    ....
  58. pmc Falls and health status in elderly women following first eye cataract surgery: an economic evaluation conducted alongside a randomised controlled trial
    Tracey H Sach
    School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
    Br J Ophthalmol 91:1675-9. 2007
    ..To evaluate the cost-effectiveness of first eye cataract surgery compared with no surgery from a health service and personal social services perspective...
  59. ncbi Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world
    Arthi Vijayaraghavan
    Mosaic Health Care Consultants, Larkspur, CA, USA
    J Acquir Immune Defic Syndr 46:91-100. 2007
    ..Determine the cost-effectiveness of initiating and monitoring highly active antiretroviral therapy (HAART) in developing countries according to developing world versus developed world guidelines...
  60. pmc Thoughts on health economics in rheumatoid arthritis
    Gisela Kobelt
    Ann Rheum Dis 66:iii35-9. 2007
    ..We will thus specifically address costs and outcome measurements in RA, as well as the need for modelling in chronic progressive diseases...
  61. ncbi Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data
    J Hjelmgren
    IHE, The Swedish Institute for Health Economics, Lund, Sweden
    Br J Dermatol 156:913-21. 2007
    ..Atopic dermatitis (AD) affects health and quality of life (QoL) and also has great impact on both healthcare costs and costs to society...
  62. pmc Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients
    Negro Roberto Dal
    Lung Dept, Orlandi General Hospital, Bussolengo, Verona, Italy
    Int J Chron Obstruct Pulmon Dis 2:169-76. 2007
    ....
  63. ncbi Retrospective cost-effectiveness analyses for polio vaccination in the United States
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, Harvard University, MA 02115, USA
    Risk Anal 26:1423-40. 2006
    ..Observed changes in the cost-effectiveness ratio estimates over time suggest the need for living economic models for interventions that appropriately change with time...
  64. ncbi Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy
    Montserrat Vera-Llonch
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Epilepsia 49:431-7. 2008
    ..To estimate the cost-effectiveness of pregabalin as add-on therapy in patients with refractory partial epilepsy...
  65. ncbi Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study
    Patrizia Berto
    School of Pharmacy, University of Padova, and PBE Consulting, Verona, Italy
    Ann Allergy Asthma Immunol 97:615-21. 2006
    ..Few data are available on the pharmacoeconomic aspects of immunotherapy...
  66. ncbi Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom
    S Morris
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex UB8 3PH, UK
    Anaesthesia 62:43-52. 2007
    ..Preliminary results suggest that relative to placebo, recombinant activated factor VII may be a cost-effective therapy to the UK National Health Service...
  67. ncbi Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
    T Younis
    Department of Medicine, Dalhousie University at Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Ann Oncol 18:293-8. 2007
    ..To determine cost-effective (CE) strategies comparing adjuvant upfront aromatase inhibitor (AI) with sequential tamoxifen (TAM) AI in postmenopausal (PM) women with breast cancer (BC)...
  68. ncbi The cost utility of strabismus surgery in adults
    Cynthia L Beauchamp
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, USA
    J AAPOS 10:394-9. 2006
    ..Our purpose was to develop a cost model for surgical care for adult strabismus, to estimate the mean cost per case, to determine the associated gain in QALYs, and to perform cost-utility analysis...
  69. doi Money matters: what to look for in an economic analysis
    Lea M Dijksman
    Department of Orthopaedic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    Acta Orthop 79:1-11. 2008
  70. ncbi A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years
    Alyson Lieban Hatten
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Clin J Pain 22:700-11. 2006
    ..In addition, it expands upon previously published data evaluating the efficacy of interdisciplinary pain management in relation to medication management...
  71. ncbi Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole
    C Skedgel
    Department of Medicine, Centre for Clinical Research, Dalhousie University, 5790 University Ave, B3H 1V7, Halifax, NS, Canada
    Breast Cancer Res Treat 101:325-33. 2007
    ....
  72. pmc Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Circulation 117:1261-8. 2008
    ....
  73. ncbi Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial
    Arthur M Feldman
    Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
    J Am Coll Cardiol 46:2311-21. 2005
    ....
  74. ncbi [Drug costs should be based on health economic benefits. A new law on drug benefits requires studies of health economic effects]
    Fredrik Berggren
    Universitetssjukhuset MAS, avdelningen för hälsoekonomi, Lunds universitet, Centrum för hälsoekonomi LUCHE
    Lakartidningen 100:2446-8. 2003
  75. ncbi Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease
    Thomas Hoffmann
    Institute of Health Economics and Clinical Epidemiology, University of Cologne, Germany
    Eur J Health Econ 5:129-35. 2004
    ..avium complex. The results were stable against a wide range of parameter variations concerning costs and incidence rates...
  76. ncbi [Cost-utility analysis; uncertainties restrict applicability]
    J N de Neeling
    Gezondheidsraad, Postbus 16 052, 2500 BB Den Haag
    Ned Tijdschr Geneeskd 148:1106-10. 2004
    ..The conclusion is that the results of a cost-utility analysis should be interpreted with caution. For the time being, cost-utility analysis cannot be used for direct comparisons of efficiency across all types of health-care services...
  77. ncbi Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis
    Elie Kurzer
    Department of Urology, The Long Island College Hospital, Downstate Medical Center, New York, USA
    Eur Urol 42:163-6. 2002
    ..Moreover, the economic burden of these therapies has been heretofore poorly described. The purpose of this study was to compare the cost effectiveness of various antibiotic treatment regimens for chronic bacterial prostatitis...
  78. ncbi Health care economic analyses and value-based medicine
    Melissa M Brown
    The Center for Value Based Medicine, Suite 210, 1107 Bethlehem Pike, Flourtown, PA 19031, USA
    Surv Ophthalmol 48:204-23. 2003
    ..It is anticipated that cost-utility analysis will play a major role in health care within the coming decade...
  79. ncbi A cost-utility analysis of therapy for amblyopia
    Jaime H Membreno
    Center for Evidence Based Health Care Economics, Flourtown, Pennsylvania 19031, USA
    Ophthalmology 109:2265-71. 2002
    ..Evaluation of the incremental cost-effectiveness of therapy for amblyopia...
  80. ncbi Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis
    Monica Maria Ortegon
    Netherlands Institute of Health Sciences, Erasmus University, Rotterdam, The Netherlands
    Diabetes Care 27:901-7. 2004
    ..To estimate the lifetime health and economic effects of optimal prevention and treatment of the diabetic foot according to international standards and to determine the cost-effectiveness of these interventions in the Netherlands...
  81. ncbi Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke
    Marjory L Moodie
    National Stroke Research Institute, Health, Heidelberg Heights, Australia
    Stroke 35:1041-6. 2004
    ..The aim of this study was to trial the use of the intervention module of the economic model, a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to facilitate evaluation and ranking of the options...
  82. ncbi Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity
    Donald D Sin
    Institute of Health Economics, Department of Medicine, University of Alberta, Edmonton, Canada
    Am J Med 116:325-31. 2004
    ..Inhaled corticosteroids reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), but their cost-effectiveness is not known...
  83. ncbi [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]
    Fredrik Borgstrom
    Centrum för hälsoekonomi, Handelshögskolan, Stockholm
    Lakartidningen 100:36-40. 2003
    ....
  84. ncbi Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany
    Hans Helmut Konig
    Health Economics Research Unit, Department of Psychiatry, University of Leipzig, Leipzig, Germany
    Pediatrics 113:e95-108. 2004
    ..To estimate the long-term cost-effectiveness of a hypothetical screening program for untreated amblyopia in 3-year-old children conducted by orthoptists in all German kindergartens in the year 2000...
  85. ncbi Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands
    K Visser
    Department of Psychiatry, University Hospital Groningen, The Netherlands
    Eur J Vasc Endovasc Surg 25:213-23. 2003
    ..to determine the societal cost-effectiveness of various management strategies, including both the diagnostic imaging work-up and treatment, for patients with intermittent claudication in The Netherlands...
  86. ncbi Value-based medicine: evidence-based medicine and beyond
    Gary C Brown
    Retina Service, Wills Eye Hospital, Jefferson Medical College, Philadelphia PA, USA
    Ocul Immunol Inflamm 11:157-70. 2003
    ..A review of the current status and the likely future of value-based medicine is addressed herein...
  87. ncbi Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
    Andreas Maetzel
    University Health Network Research Institute, University of Toronto, Toronto, Ontario, Canada
    Pharmacoeconomics 21:501-12. 2003
    ..The perspective of the study was from the viewpoint of a US healthcare provider...
  88. ncbi A comparison of surgical and medical costs for refractory epilepsy
    Michael Platt
    Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
    Epilepsia 43:25-31. 2002
  89. ncbi Screening for lung cancer with CT: a preliminary cost-effectiveness analysis
    Thomas N Chirikos
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL 33612, USA
    Chest 121:1507-14. 2002
    ..To appraise the potential cost-effectiveness of lung cancer screening with CT...
  90. ncbi Health economics--what the nephrologist should know
    Andrew J Palmer
    Nephrol Dial Transplant 20:1038-41. 2005
  91. ncbi Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate
    Charles N Ellis
    Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA
    J Am Acad Dermatol 46:242-50. 2002
    ..Because health care resources are limited, therapeutic regimens should be assessed for their relative costs and effectiveness...
  92. ncbi Economic evaluation of epilepsy treatment: a review of the literature
    Dominic C Heaney
    Institute of Psychiatry, Kings College London, England
    Epilepsia 43:10-6. 2002
    ..Health outcome measures are defined and data sources described. Methods for assessing the direct and indirect costs, and/or cost savings, with a treatment's use, are explored. Directions for future research are identified and discussed...
  93. ncbi Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service
    Monia Marchetti
    Laboratory of Medical Informatics, Institute for Scientific Research and Health Care, Pavia, Italy
    Clin Ther 26:1546-61. 2004
    ..Third-generation aromatase inhibitors are effective alternatives to tamoxifen in patients with advanced breast cancer. However, their acquisition costs might burden fixed-budget health care systems...
  94. ncbi Economic evaluation of proton radiation therapy in the treatment of breast cancer
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Radiother Oncol 75:179-85. 2005
    ..It is therefore important to evaluate whether the medical benefits of proton therapy are large enough to justify the higher treatment costs, compared with conventional radiation therapy...
  95. ncbi Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Perit Dial Int 22:39-47. 2002
    ..Our aim was to compare both health-related quality of life and costs for hemodialysis (HD) and peritoneal dialysis (PD) in a defined population...
  96. ncbi The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women
    M Stevenson
    School of Health and Related Research ScHARR, University of Sheffield, UK
    Health Technol Assess 11:1-134. 2007
    ..This considers secondary prevention in women who have sustained a previous fracture and primary prevention in those women without a previous fracture, as women with osteoporosis are asymptomatic until a fracture is sustained...
  97. ncbi The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation
    E Loveman
    Southampton Health Technology Assessments Centre, University of Southampton Science Park, Southampton, UK
    Health Technol Assess 14:1-204. 2010
    ..To assess the clinical effectiveness and cost-effectiveness of topotecan as second-line treatment for small cell lung cancer (SCLC)...
  98. ncbi Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden
    Michael Willis
    The Swedish Institute for Health Economics, Lund, Sweden
    Appl Health Econ Health Policy 8:377-86. 2010
    ..Many countries, including the UK, are signalling shifts in this direction. Several countries, including Sweden, have already adopted this approach and offer good insight into the benefits and pitfalls in actual practice...
  99. ncbi A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer
    R Collins
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 11:iii-iv, xv-xviii, 1-179. 2007
    ..The main comparators considered were other established chemotherapy regimens and best supportive care...
  100. ncbi Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis
    John R Wingard
    University of Florida College of Medicine, Gainesville, 32610, USA
    Clin Ther 27:960-9. 2005
    ..7% and 62.8% of patients, respectively) and exhibited a generally better safety profile, particularly with respect to impaired renal function (IRF) (P = 0.02)...
  101. ncbi The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model
    M Bond
    Peninsula Technology Assessment Group PenTAG, Peninsula Medical School, Universities of Exeter and Plymouth, UK
    Health Technol Assess 13:iii-iv, xi-xiv, 1-156. 2009
    ..To review the evidence for the effectiveness and cost-effectiveness of storing kidneys from deceased donors prior to transplantation, using cold static storage solutions or pulsatile hypothermic machine perfusion...

Research Grants62

  1. Transforming PCI Informed Consent into an Evidence-based Decision-making Tool
    John A Spertus; Fiscal Year: 2010
    ..Our research team has extensive experience in the construction of economic models in PCI...
  2. Mechanisms Underlying Social Cooperative Behavior
    LUKE JOSEPH CHANG; Fiscal Year: 2010
    ..This idea, based on notions of guilt from social psychology, has found support in recent economic models in which beliefs about other's beliefs are incorporated into individual utility functions...
  3. EVALUATION OF THE FREQUENCY OF VISUAL FIELD TESTING IN OCULAR HYPERTENSIVES
    Steven M Kymes; Fiscal Year: 2010
    ..Conducting sensitivity analyses with this decision model will permit evaluation of the consequences of a delay in case identification beyond the characteristics of the OHTS sample. ..
  4. Neuroeconomics of Framing Effects and Risk Attitudes in Early Dementia
    Winston Chiong; Fiscal Year: 2013
    ..Ming Hsu, a neuroeconomist at UC Berkeley with expertise in applying economic models to neural data. Finally, consultant Dr...
  5. Hospital-Physician Gainsharing
    JONATHAN DAVID KETCHAM; Fiscal Year: 2010
    ..The project also includes one exploratory aim: to develop and test economic models that accurately predict physicians'responses to alternative incentive programs, including differently ..
  6. Enhance Facilities for Infectious Disease Imaging
    RALPH E SMITH; Fiscal Year: 2010
    ....
  7. Biological vector control reducing arboviruses, including Dengue and Chikungunya
    JAMES WILLIAM MAINS; Fiscal Year: 2012
    ..A regulatory pathway is defined. Moreover, the approach will be broadly applicable to additional mosquito vector species (e.g., Ae. aegypti, Culex pipiens, etc.) and appropriate for areas outside the USA. ..
  8. Eliciting Maternal Knowledge about the Technology of Skill Formation
    FLAVIO CUNHA; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): In general, economic models of human development assume that mothers have rational expectations about the technology of skill formation, that is, about the process that determines how their offspring ..
  9. Risk, Insurance and the Family
    Robert M Townsend; Fiscal Year: 2013
    ..partnerships with financial institutions on the ground and systemic research informed via the use of detailed economic models, this project aims to create a more efficient financial system that supports the growth and development of ..
  10. Psychological and Neural Mechanisms of Pain Valuation
    Tal Yarkoni; Fiscal Year: 2012
    ..by supplementing my background in cognitive neuroscience with a better understanding of behavioral economic models and techniques. My development in this area will be supported by Dr...
  11. Aging and Altruism: Towards a Neuroeconomic Model of Age-Related Changes in Givin
    Ulrich Mayr; Fiscal Year: 2009
    ..The objective is to see if economic models can explain these behaviors in the age groups that are most likely to give and to vote, and to see how age ..
  12. The intrinsic cost of cognitive control: Neural foundations and behavioral impact
    Matthew M Botvinick; Fiscal Year: 2013
    ..Can the labor-supply model account for shifts in control allocation over time, including so-called 'ego-depletion'effects? ..
  13. A User-Friendly Epidemic-Economic Model of Diagnostic Tests for Tuberculosis
    DAVID WESLEY DOWDY; Fiscal Year: 2013
    ....
  14. Integrated Samples of Latin American Censuses
    MATTHEW SOBEK; Fiscal Year: 2013
    ..Accordingly, the data series provides a unique laboratory for the study of health and demographic processes, and provides the empirical foundation we need for developing and testing social and economic models.
  15. The Predictors and Consequences of Cohabitation Dissolution versus Divorce
    CLAIRE M KAMP DUSH; Fiscal Year: 2011
    ..me 1) to gain expertise in demographic methods and integrate these methods with social, psychological, and economic models of family and human development, 2) the time needed to complete my research plan and apply the methods I will ..
  16. Integrated Lifecycle Approach to the Development of Health &Other Capabilities
    James J Heckman; Fiscal Year: 2013
    ..To achieve this goal, we propose to develop and apply economic models to analyze numerous large- scale data sets with life-cycle information to investigate the sources of health ..
  17. Cost Effectiveness of Anticoagulation Versus Genetic Testing of CYP2C9 & VKORC1 G
    Anna Teschemaker; Fiscal Year: 2009
    ..The current study is proposed to assess the cost-effectiveness of genetic testing for the identified genes. ..
  18. Improved Models to Inform Tobacco Product Regulation
    STANTON ARNOLD GLANTZ; Fiscal Year: 2013
    ..This TCORS includes five full projects (one on economic models, two on behavioral models, and two on cardiovascular and pulmonary disease models), two developmental ..
  19. Evaluating the social influences that impact vaccination decisions
    Alison P Galvani; Fiscal Year: 2013
    ..To do so, we will use epidemiological-economic models including game theory and network models of influenza transmission, parameterized by psychological, economic ..
  20. Relative Price, Payer Mix and Regional Variations in Medical Care
    JONATHAN DAVID KETCHAM; Fiscal Year: 2013
    ..These results will inform which policies, if any, should be implemented to reduce these variations. ..
  21. Synthesizing and Interpreting the Evidence on Early Interventions
    James J Heckman; Fiscal Year: 2011
    ..This translates into building economic models of skill formation that take into account cognitive and socioemotional skills, as well as models that ..
  22. Crimson - i2b2 integration for high-throughput, scalable sample collection
    Lynn Bry; Fiscal Year: 2010
    ....
  23. CHILD CUSTODY & MONEY TRANSFERS IN DIVORCE NEGOTIATIONS
    H Peters; Fiscal Year: 1992
    ..In this proposal the Stanford Child Custody Data are used to estimate the contribution of each of these factors to the problem of non-payment of child support payments...
  24. AN INVESTIGATION OF THE VIATICAL SETTLEMENTS MARKET
    Dana Goldman; Fiscal Year: 2005
    ..the viatical settlements market in states with different regulatory environments; (3) Empirically estimate economic models of market behavior using actual transaction data; and (4) Simulate the welfare implications of price ..
  25. IPUMS Redesign
    STEVEN RUGGLES; Fiscal Year: 2013
    ..Accordingly, the data series provides a unique laboratory for the study of health and demographic processes, and provides the empirical foundation we need for developing and testing social and economic models.
  26. EFFECTS OF PRICE ON ILLEGAL DRUG USE
    Michael Grossman; Fiscal Year: 1993
    ....
  27. MEDICAL OUTCOMES IN THE PRICING OF HOSPITAL PROCEDURES
    Avi Dor; Fiscal Year: 2001
    This proposal utilizes economic models of pricing behavior to assess the effects of hospital quality on the prices of major medical hospital procedures. Hospital quality is defined in terms of medical outcomes, i.e...
  28. Child Gender and Family Behavior
    Shelly Lundberg; Fiscal Year: 2005
    ..Our economic models incorporate differences in parental preferences towards, and differences in productivity in raising, boys and ..
  29. Provider Payment Reform and Implications for Health Care Costs
    Zirui Song; Fiscal Year: 2013
    ..The project will also develop two simple economic models, a normative model of physician optimal referral and a positive model of physician specialization, to ..
  30. Population-level Analyses of Multi-drug Consumption
    Siddharth Chandra; Fiscal Year: 2007
    ..will enable the pursuit of at least six specific aims, including analyses of (i) the addictiveness (using economic models of addiction) of each of these substances in a multi-substance setting using legal data, (ii) substitution ..
  31. IMPACT TOTAL WORKLOAD--MATERNAL POSTPARTUM HEALTH/QOL
    Patricia McGovern; Fiscal Year: 2003
    ..The research model is adapted from economic models of health and household production function theory, and integrates elements of the biopsychosocial approach ..
  32. COST-BENEFIT ANALYSIS OF HEART DISEASE RESEARCH
    Deborah Lubeck; Fiscal Year: 1980
    ..Finally, strategies for evaluating and implementing assessments of future medical innovations will be drawn from the data gathered and presented in this study. ..
  33. RETIREMENT AND MARITAL BARGAINING
    Shelly Lundberg; Fiscal Year: 1999
    DESCRIPTION (Adapted from the Applicant's Abstract): Economic models of retirement behavior typically examine the optimal behavior of a single individual who faces alternative streams of utility over the remainder of his or her life...
  34. National Impact of IT Investments on Hospital Quality
    Stephen Parente; Fiscal Year: 2009
    ..This research represents a collaborative effort of investigators at the University of Minnesota, Carnegie Mellon University, and the Medical University of South Carolina. ..
  35. BLACK-WHITE DIFFERENCES IN THE USE OF LONG-TERM CARE
    Raynard Kington; Fiscal Year: 1993
    ..Statistical techniques will correct for the competing risks of death and nursing home admission and the non-random selection of parents who become significantly impaired...
  36. COSTS OF DRUG TREATMENT UNDER PRIVATE INSURANCE
    Roland Sturm; Fiscal Year: 2000
    ..specific benefit designs (limits, deductibles, copayments) on access, intensity of care, and cost, adapting economic models of health care demand. 4...
  37. Screening Technology and Outcomes Project in Stroke
    Karen Furie; Fiscal Year: 2005
    ..This research will allow develop of economic models based on the costs and outcomes of different subtype of strokes...
  38. Improving the Quality and Safety of Regional Surgical P*
    Michael Higgins; Fiscal Year: 2004
    ..abstract_text> ..
  39. "WORKSHOPS IN FORMAL AND QUANTITATIVE DEMOGRAPHY"
    Shripad Tuljapurkar; Fiscal Year: 2005
    ..recent work describing populations in transition, stochastic dynamics, collective dynamics, and demographic-economic models. Finally, formal demography includes the development of these methods in specific substantive contexts ..
  40. DEMAND FOR ALCOHOL TREATMENT SERVICES
    JAYANTA BHATTACHARYRA; Fiscal Year: 2001
    ..For example, using our framework, we will be able to accurately estimate the costs of parity legislation for alcoholism treatment. ..
  41. TEENAGE DECISION MAKING, SCHOOLING, AND FERTILITY
    DONALD PARSONS; Fiscal Year: 1990
    ..model will be developed that stresses the cost of avoiding fertility, in contrast to traditional economic models that focus on the quantity/quality tradeoff...
  42. Value of Health Information Exchange in Ambulatory Care
    JOSEPH OVERHAGE; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  43. Applied Research on Antimicrobial Resistance (AR)
    Ruth Lynfield; Fiscal Year: 2006
    ..This is the first time a society-wide estimate of the cost of resistance has been attempted. ..
  44. Obesity Among Older Americans
    Dana Goldman; Fiscal Year: 2009
    ..We will explore the effect of this variation in weight on health. Finally, we propose policy analyses based on our work. We will investigate the effect of hypothetical food taxation policies on weight, health, and nutrition. ..
  45. PUBLIC HLTH IMPACT AND COST EFFECTIVENESS OF HIV INTERV
    Edward Kaplan; Fiscal Year: 2000
    ..We propose to develop and apply mathematical and economic models to evaluate interventions and thereby to inform the allocation of scarce resources...
  46. BENEFITS OF TREATMENT SERVICES
    GARY ZARKIN; Fiscal Year: 2000
    ..abstract_text> ..
  47. Experiments to Measure Consumption and Attitudes
    Joachim Winter; Fiscal Year: 2003
    ..to reliable consumption data, information on households' attitudes is required to estimate some recent economic models that provide more flexible and realistic alternatives to the established life-cycle theory of household ..
  48. ECONOMIC ASPECTS OF YOUNG WOMENS DRINKING
    ALISON SNOW JONES; Fiscal Year: 2002
    ..b>Economic models of addiction and labor supply will be estimated for both men and women...
  49. ECONOMIC ASPECTS OF YOUNG WOMENS DRINKING
    ALISON SNOW JONES; Fiscal Year: 2000
    ..b>Economic models of addiction and labor supply will be estimated for both men and women...
  50. Nonhuman Primate Models of Speedball Abuse
    Roger Spealman; Fiscal Year: 2007
    ..The results of our proposed research will provide needed information about neuropharmacological mechanisms underlying speedball addiction and potential targets for medication development. ..
  51. Economic Analysis of Depression Treatment Process
    Ming Tai Seale; Fiscal Year: 2006
    ..Such an experience will enable the applicant to use an interdisciplinary approach in a larger future study on how to alter incentives to promote patient-centered mental health treatment process. ..
  52. DISCOVERY AND DEVELOPMENT OF THERAPEUTIC COMPOUNDS
    Joseph McCune; Fiscal Year: 1993
    ..In addition, regulatory perspectives and principles germane to the development process as well as economic models for cost-effective introduction and evaluation of new therapeutic compounds will be discussed...
  53. A Gender-Economic Model (GEM) of HIV Risk in Women
    Cynthia Gomez; Fiscal Year: 2006
    ..abstract_text> ..
  54. EXTENDED ECONOMIC IMPACT ASSESSMENT OF AIDS INTERVENTION
    Anke Richter; Fiscal Year: 2000
    ..2. Identify the parameters (such as individual HIV risk behaviors) to which the mathematical epidemic and economic models are most sensitive and thereby identify targets for future policy and intervention programs for substance ..
  55. EFFECTS OF CHANGES IN LIVING ARRANGEMENTS ON CHILDREN
    Nazli Baydar; Fiscal Year: 1993
    ..A conceptual framework integrating sociological, developmental, psychological and economic models of family dynamics is formulated...
  56. Time Series Modeling of Trends in Medication Prescribing
    RANDALL STAFFORD; Fiscal Year: 2004
    ..Results from the analysis will be relevant to efforts to design and implement clinical and health policies to encourage the effective and cost-effective use of medications. ..
  57. WHY DON'T AMERICANS SAVE ENOUGH FOR RETIREMENT?
    David Laibson; Fiscal Year: 2001
    ..The proposed research will analyze the undersaving problem by developing economic models with psychological microfoundations...
  58. SUCCESSFUL AGING--ROLE OF SUSTAINED PARENTAL INVESTMENT
    Elizabeth Hill; Fiscal Year: 1999
    ..Our conceptual model is derived from economic models of health as an investment and overlapping models of life history from behavioral ecology...
  59. Intergenerational Financial Transfers
    Michael Hurd; Fiscal Year: 2007
    ..The research will be based on data from eight waves of the Health and Retirement Study. ..
  60. International Migration Patterns of Health Professionals
    Peter Hussey; Fiscal Year: 2004
    ....
  61. Dialysis Facility Management
    Eric Eisenstein; Fiscal Year: 2003
    ..abstract_text> ..
  62. HRQL Impact of Chronic Conditions and Comorbidity Burden
    Patrick Sullivan; Fiscal Year: 2006
    ..S. [unreadable] [unreadable]..